Decision support system for predicting metabolic risks in patients with comorbid non-alcoholic fatty liver disease and gallstone disease after cholecystectomy

183 patients with non-alcoholic fatty liver disease (NAFLD) were included into the case control study. Objective. Development a medical decision support system to improve the prediction of metabolic risks in persons with comorbid NAFLD and gallstone disease (GD) after cholecystectomy. Materials and methods. The main group was represented by patients with NAFLD and GD (n = 88), of which 53 patients underwent cholecystectomy. The comparison group was represented by patients with NAFLD without GD (n = 95). A standard laboratory and instrumental examinations were performed, including elastometry to assess of the stage of liver fibrosis and assessment of the level of hormones leptin, its soluble receptor, adiponectin and insulin. Results. Patients suffering from GD and NAFLD had a symptom of dyspepsia and general weakness. High prevalence of type 2 diabetes (rs = 0.164; р ≤ 0.01) and сoronary heart disease (25.00 % versus 9.47 % in the comparison group; р ≤ 0.01), high level of LDL and GGT (rs = 0.228, р ≤ 0.01 and rs = 0.298, р ≤ 0.01) were found in patients with GD after cholecystectomy. The phenomenon of insulin and leptin resistance, high levels of adiponectin were detected in patients suffering from NAFLD and GD. Hyperleptinemia was observed in NAFLD patients with GD after cholecystectomy (H = 5.812, p ≤ 0.05, rs = 0.313, p ≤ 0.05). Cholecystectomy in patients suffering from GD and NAFLD was associated with the formation of progressive stages of liver fibrosis (rs = 0.366; р ≤ 0.01). Conclusion. We have developed a decision support system to assess of the possibility of cholecystectomy in patients with NAFLD and GD according to the level metabolic risk of cardiovascular diseases and NAFLD progression.

1. EASL–EASD–EASO. Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. // Journal of Hepatology. 2016. V. 64, N 6. P. 1388–1402. DOI: 10.1016/j.jhep.2015.11.004.

2. Ивашкин В.Т., Маевская М. В., Павлов Ч. С. и др. Клинические рекомендации по диагностике и лечению неалкогольной жировой болезни печени Российского общества по изучению печени и Российской гастроэнтерологической ассоциации. // Рос. журн. гастроэнтерологии, гепатологии, колопроктологии. 2016. Т. 26, № 2. С. 24–42. https://doi.org/10.22416/1382–4376–2016–26–2–24–42

3. Targher G, Byrne CD, Lonardo A et al. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis. // J Hepatol. 2016. V. 65. P. 589–600. DOI: 10.1016/j.jhep.2016.05.013.

4. Parambir S. Dulail, Siddharth Singh, Janki Patel [et al.]. Increased risk of mortality by fibrosis stage in non-alcoholic fatty liver disease: Systematic Review and Meta- analysis. // Hepatology. 2017. V. 65, N. 5. P. 1557–1565. DOI: 10.1002/hep.29085.

5. Pappachan JM, Babu S, Krishnan B, Ravindran NC. Non-alcoholic Fatty Liver Disease: A Clinical Update. // J Clin Translat Hepatol. 2017. N 5. P. 384–93. DOI: 10.14218/JCTH.2017.00013.

6. Кролевец Т.С., Ливзан М. А. Клинико-лабораторные маркеры прогнозирования фиброза печени у лиц с неалкогольной жировой болезнью печени. // Экспериментальная и клиническая гастроэнтерология. 2018. Т. 155, № 7. С. 43–51. eLIBRARY ID: 38200880.

7. Ливзан М.А., Лаптева И. В., Кролевец Т. С., Черкащенко Н. А. Лептинорезистентность у пациентов с неалкогольной жировой болезнью печени, ассоциированной с ожирением и избыточной массой тела. // Медицинский совет. 2015. № 13. С. 58–63. DOI: 10.21518/2079–701X2015–13–58–63.

8. Da Zhou, Jian-Gao Fan. Microbial metabolites in non-alcoholic fatty liver disease. // World J Gastroenterol. 2019. V. 25, N 17. P. 2019–2028. DOI: 10.3748/wjg.v25.i17.2019.

9. Ливзан М.А., Гаус О. В., Николаев Н. А., Кролевец Т. С. НАЖБП: коморбидность и ассоциированные заболевания. // Экспериментальная и клиническая гастроэнтерология. 2019. Т. 170, № 10. С. 57–65. DOI: 10.31146/1682–8658-ecg‑170–10–57–65.

10. Veeravich Jaruvongvanich, Anawin Sanguankeo & Sikarin Upala. Significant Association Between Gallstone Disease and Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. // Digestive Diseases and Sciences. 2016. N 61. P. 2389–2396. DOI: 10.1007/s10620–016–4125–2.

11. Lailai Fan, Baihui Chen, Zhijuan Dai. The relation between gallstone disease and cardiovascular disease. // S Cien Tifi C Repor TS. 2017. N 7. P. 15104. DOI: 10.1038/s41598–017–15430–5.

12. Nascimbeni F.; Ballestri S.; Machado M. V.; Mantovani A.; Cortez-Pinto H.; Targher G.; Lonardo A. Clinical relevance of liver histopathology and different histological classifications of NASH in adults. Expert. Rev. // Gastroenterol. Hepatol. 2018. N 12. P. 351–367. DOI: 10.1080/17474124.2018.1415756.

13. Гаус О.В., Ахмедов В. А. Иммунологические параллели в течении метаболического синдрома, ассоциированного с желчнокаменной болезнью. // Фундаментальные исследования. 2013. № 7. С. 51–54.

14. Di Ciaula A, Wang DQ, Portincasa P. Cholesterol cholelithiasis: part of a systemic metabolic disease, prone to primary prevention. // Expert Rev Gastroenterol. Hepatol. 2019. V. 13, N 2. P. 157–171.

15. Ахмедов В.А., Гаус О. В. Поражение органов гепатобилиарной системы и поджелудочной железы при ожирении. // Терапевтический архив. 2017. Т. 89, № 1. С. 128–133.

16. Ix J.H.; Sharma K. Mechanisms linking obesity, chronic kidney disease, and fatty liver disease: The roles of fetuin-A, adiponectin, and AMPK. // J. Am. Soc. Nephrol. 2010. N 21. P. 406–412.

17. Драпкина О.М., Корнеева О. Н., Палаткина Л. О. Адипокины и сердечно- сосудистые заболевания: патогенетические параллели и терапевтические перспективы. // АГ. 2011. № 3. URL: https://cyberleninka.ru/article/n/adipokiny-i-serdechno-sosudistye-zabolevaniya-patogeneticheskie-paralleli-iterapevticheskie-perspektivy (дата обращения: 20.03.2019).

18. Saxena Neeraj K. Anania Adipocytokines and hepatic fibrosis / Neeraj K. Saxena, Frank A. Anania. // Trends in Endocrinology and Metabolism. 2015. Vol. 26, N 3. P. 153–161.

19. Роль лептина и лептинорезистентности в формировании неалкогольной жировой болезни печени у лиц с ожирением и избыточной массой тела. / Ливзан М. А., Лаптева И. В., Миллер Т. С. // Экспериментальная и клиническая гастроэнтерология. 2014. № 8 (108). С. 27–33.

20. Javor ED, Ghany MG, Cochran EK, Oral EA, de Paoli AM, Premkumar A, Kleiner DE, Gorden P. Leptin reverses nonalcoholic steatohepatitis in patients with severe lipodystrophy. // Hepatology. 2005. N 41. P. 753–760.

21. Méndez-Sánchez N., Ponciano-Rodrigoez G. Effects of leptin on biliary lipids: potential consequences for gallstone formation and therapy in obesity. // Curr. Drug Targets Immune Endocr. Metabol. Disord. 2005. V. 5, N 2. P. 203–208.

22. Sarac S., Atamer A., Atamer Y. [et al.] Leptin levels and lipoprotein profiles in patients with cholelithiasis. // Journal of International Medical Research. 2015. V. 43, N 3. P. 385–392. DOI: 10.1177/0300060514561134.

23. Milner K., van der Poorten D., Xu A., Bugianesi E., Kench J., Lam K., Chisholm D., George J. Adipocyte fatty acid binding protein levels relate to inflammation and fibrosis in nonalcoholic fatty liver disease. // Hepatology. 2009. N 49 (6). P. 1926–1934.

24. Ивашкин В.Т., Маев И. В., Баранская Е. К., Охлобыстин А. В., Шульпекова Ю. О., Трухманов А. С., Шептулин А. А., Лапина Т. Л. Рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению желчнокаменной болезни. // Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2016. Т. 26, № 3. С. 64–80. https://doi.org/10.22416/1382–4376–2016–26–3–64–80

25. Ruhl C.E., Everhart J. E. Relationship of non-alcoholic fatty liver disease with cholecystectomy in the US population. // Am J Gastroenterol. 2013, Jun. V. 108, N 6. P. 952–958.

26. Kwak MS, Kim D, Chung GE, et al. Cholecystectomy is independently associated

27. with nonalcoholic fatty liver disease in an Asian population. // World J Gastroenterol. 2015. N. 21. P. 6287–6295.

28. Nervi F, Arrese M. Cholecystectomy and NAFLD: does gallbladder removal have metabolic consequences? // Am J Gastroenterol. 2013. V. 108, N. 6. P. 959–961.

29. ChenY, Yu Tian SW. Cholecystectomy as a risk factor of metabolic syndrome: from epidemiology to biochemical mechanisms. // Laboratory Investigation. 2018. N. 98. P. 7–14.

30. Fairfield CJ, Wigmore SJ, Harrison EM. Gallstone Disease and the Risk of Cardiovascular Disease. // Sci Rep. 2019. V. 9, N 1. P. 5830.